Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01449370
Other study ID # INK1117-001
Secondary ID
Status Completed
Phase Phase 1
First received August 11, 2011
Last updated November 4, 2016
Start date October 2011
Est. completion date January 2016

Study information

Verified date November 2016
Source Takeda
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationSpain: Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of MLN1117 when administered orally in subjects with advanced solid malignancies.


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date January 2016
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects have had their PIK3CA gene mutation status assessed prior to enrolling into the study

- Subjects must have documented disease progression prior to enrolling into the study

- locally advanced or metastatic solid tumors with the exception of primary brain tumor, and have failed or are not eligible for standard of care therapy.

- Age = 18 years, including males and females;

- ECOG performance status (PS) 0-1;

- Adequate organ function;

- Male subjects must be surgically sterile or must agree to use physician-approved contraception during the study and for 30 days following the last study drug administration;

- Ability to swallow oral medications;

- Ability to understand and willingness to sign informed consent prior to initiation of any study procedures;

- For women of child-bearing potential, negative serum pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of birth control from 30 days prior to the first study drug administration to 30 days following the last study drug administration

Exclusion Criteria:

- Diagnosis of primary brain tumor; untreated brain metastasis or history of leptomeningeal disease or spinal cord compression;

- Received prior cancer or other investigational therapy within 2 weeks prior to the first administration of study drug;

- Have received a systemic corticosteroid within one week prior to the first administration of study drug;

- Clinically significant cardiac disease;

- Myocardial infarction or unstable angina within 6 months prior to the first administration of study drug;

- Malabsorption ;

- Poorly controlled diabetes mellitus;

- Pregnancy (positive serum or urine pregnancy test) or breast feeding;

- Untreated brain metastasis or history of leptomeningeal disease or spinal cord compression;

- Failed to recover from the reversible effects of prior anticancer therapies;

- Have received a selective PI3K-alpha inhibitor

- Other clinically significant co-morbidities, such as uncontrolled pulmonary disease, active central nervous system (CNS) disease, active infection, or any other condition that could compromise the subject's participation in the study

- Known human immunodeficiency virus (HIV) infection

- Have a secondary malignancy within the last 3 years prior to first dose of study drug, excluding treated non-melanoma skin cancer, carcinoma in situ, or locally-treated prostate cancer

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
MLN1117
oral administration of MLN1117, daily and intermittent schedules.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Millennium Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Tolerated Dose (MTD) 3 week cycle Yes
Primary Number of Adverse Events (AE) From first dose of study drug through 30 days after last dose of study drug Yes
Secondary Plasma level of MLN1117 Pharmacokinetic profile Days 1-21 of Cycles 1 & 2 No
Secondary Biomarker levels Pharmacodynamic profile in samplings of skin and/or tumor biopsies pre- and post-treatment. Day 1 of Cycle 2 (Arms B & C only) No
Secondary Objective response rate Complete response and partial response Day 1 of Cycles 3 and beyond and at termination visit No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03993873 - Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET Phase 1/Phase 2
Recruiting NCT05494918 - First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant Tumors Phase 1
Completed NCT02281409 - Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01928459 - Phase 1b Trial of BGJ398/BYL719 in Solid Tumors Phase 1
Recruiting NCT06031441 - A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03059823 - A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors Phase 1
Terminated NCT03573544 - This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. Phase 1/Phase 2
Active, not recruiting NCT03893955 - A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00878423 - Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors Phase 1
Withdrawn NCT00149019 - Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies. Phase 2
Recruiting NCT03093116 - A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Phase 1/Phase 2
Terminated NCT03854227 - A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors Phase 1
Recruiting NCT04094610 - A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Phase 1/Phase 2
Active, not recruiting NCT01543763 - Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors Phase 1
Terminated NCT02228811 - A Study of DCC-2701 in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT05853367 - Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) Phase 1
Completed NCT02097810 - Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. Phase 1
Recruiting NCT05836324 - A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors Phase 1
Completed NCT03910530 - A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT00148993 - Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors Phase 1/Phase 2